Posizioni attive di Floris van Delft
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Direttore Tecnico/Scientifico/R&S | 01/01/2010 | - |
| Fondatore | 01/01/2010 | - |
Storia della carriera di Floris van Delft
Precedenti posizioni note di Floris van Delft
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Radboud University Nijmegen | Corporate Officer/Principal | - | - |
Formazione di Floris van Delft
| University of Leiden | Doctorate Degree |
Statistiche
Distribuzione geografica
| Paesi Bassi | 4 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Doctorate Degree | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Floris van Delft
- Esperienza
